. 2021 Feb 15;22(4):1918. doi: 10.3390/ijms22041918

Table 3.

Association between CCL5 and the clinicopathological factors in CCR1-negative/CCR3-positive/CCR5-negative breast carcinoma cases and other cases.

Clinicopathological Factors	CCR1-Negative/CCR3-Positive/ CCR5-Negative Cases			Others
	CCL5 Status		p-Value	CCL5 Status		p-Value
	Negative (n = 23)	Positive (n = 11)	p-Value	Negative (n = 49)	Positive (n = 28)	p-Value
Stage
I	15	4	0.27	26	18	0.30
II	4	4		13	8
III	4	3		10	2
Pathological T Factor
pT1	18	4	0.0017	30	21	0.22
pT2-4	5	7	0.0017	19	7	0.22
Lymph Node Metastasis
Negative	18	5	0.056	31	21	0.29
Positive	5	6	0.056	18	7	0.29
Histological Grade
1 (well)	8	0	0.0015	24	11	0.35
2 (intermediate)	12	3		19	10
3 (poor)	3	8		6	7
ER
Negative	2	5	0.013	6	8	0.074
Positive	21	6	0.013	43	20	0.074
PR
Negative	5	9	0.0009	10	11	0.074
Positive	18	2	0.0009	39	17	0.074
HER2
Negative	20	10	0.74	43	23	0.50
Positive	3	1	0.74	6	5	0.50
Ki67 LI (%) *	13 (1–49)	22 (3–44)	0.037	9 (160)	12 (1–49)	0.44
MVD *	22 (6–52)	40 (14–106)	0.025	27 (3–101)	28.5 (7–82)	0.38

*; Data were presented as median (minimum–max). All other values represent the number of cases. p < 0.05 was considered significant and described in boldface, and 0.05 ≤ p < 0.1 was described in italic. ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, LI: labeling index, MVD: microvessel density and, PR: progesterone receptor.